REG - Argent Biopharma Ltd - Company Presentation

Argent BioPharmaAnnouncement

01/07/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240701:nRSA5463Ua&default-theme=true

RNS Number : 5463U  Argent Biopharma Limited  01 July 2024

 

1 July 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Company Presentation

 

Argent BioPharma, an innovative multidisciplinary drug discovery company
within the biopharmaceutical sector, announces the publication of its Company
Presentation for June 2024 which may be accessed via the following link:

 

https://www.investi.com.au/api/announcements/rgt/ed231bfb-b84.pdf
(https://www.investi.com.au/api/announcements/rgt/ed231bfb-b84.pdf)

 

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.co (mailto:info@argentbiopharma.co) m   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

 UK IR/PR Advisers                                            UK Corporate Broker

 IFC Advisory                                                 Shore Capital

 Graham Herring / Tim Metcalfe / Zach Cohen                   Toby Gibbs / James Thomas / Lucy Bowden

 +44 203 934 6630                                             +44 (0)207 408 4090

 argentbiopharma@investor-focus.co.uk
 (mailto:argentbiopharma@investor-focus.co.uk)

 

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; ORCQB: RGTLF) is
a Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to
providing accessible medical treatments for unmet medical needs, to bridge the
gap where medical solutions currently fall short.  The Group focuses on the
Multidisciplinary method with Nanotechnology, developing multi-target
therapies for comprehensive disease management, especially concerning to the
Central nervous system ("CNS")
(https://www.kenhub.com/en/library/anatomy/the-central-nervous-system) and
Immunology treatments.

 

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCRBMATMTAMMII